Metraipolis › archive › dc_fcb8e75d223a

Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics — Europe PMC PMID:40895536

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40895536
DOI
10.3389/fimmu.2025.1646141
License (as archived)
solo-consultazione
Archived
2026-11-10T15:02:31.432Z
SHA-256 of the archived text
fafeaf022790709adc179cf86eae08296143cf940ddacff3099c7b13f4289a7b
Stable URL of this page
https://metraipolis.com/documento/dc_fcb8e75d223a

How to cite

Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics — Europe PMC PMID:40895536 — Europe PMC (en), https://europepmc.org/article/MED/40895536 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fcb8e75d223a (Metraipolis archive dc_fcb8e75d223a, sha256 fafeaf022790709adc179cf86eae08296143cf940ddacff3099c7b13f4289a7b)
BibTeX
@misc{dcfcb8e75d223a,
  title = {Prioritizing FDA approved therapeutics for treating sepsis phenotypes: A network modeling approach based on neutrophil proteomics — Europe PMC PMID:40895536},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40895536},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fcb8e75d223a; sha256 fafeaf022790709adc179cf86eae08296143cf940ddacff3099c7b13f4289a7b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40895536. Agents can read the archived copy with the MCP tool read_document.